广生堂：创新疗法加速落地，乙肝登峰计划获突破

Group 1 - The core viewpoint of the news is that Guangshengtang has made significant progress in the clinical development of innovative drugs, particularly with the approval of the clinical trial for the combination therapy GST-HG131 and GST-HG141 for chronic hepatitis B [1][2] - The approved Phase II clinical study is based on preclinical and clinical research results, showing that GST-HG131 has a significant inhibitory effect on HBsAg, while GST-HG141 significantly suppresses and depletes HBV DNA and pgRNA, indicating a complementary antiviral mechanism [1] - The trial aims to evaluate the safety, tolerability, and efficacy of the combination therapy in chronic hepatitis B patients, providing a more effective treatment option for patients [1] Group 2 - Guangshengtang has been intensifying its focus on innovative drug research and development, resulting in a rich pipeline of innovative drugs due to sustained R&D investment and favorable policies [2] - The company has established a matrix of innovative drugs covering multiple therapeutic areas, with six new drugs in the pipeline, including the core product GST-HG141, which has received breakthrough therapy designation from CDE and is about to enter Phase III clinical trials [2] - The series of breakthroughs indicates that Guangshengtang is accelerating its transformation from a traditional pharmaceutical company to an innovation-driven pharmaceutical enterprise [2]